Vestmark Advisory Solutions Inc. Has $1.89 Million Stake in Illumina, Inc. $ILMN

Key Points

• Vestmark Advisory Solutions Inc. increased its holdings in Illumina, Inc. by 38.4%, now owning a total of 23,830 shares valued at approximately $1.89 million.
• Illumina reported earnings per share (EPS) of $1.19, surpassing analyst expectations of $1.02, despite a year-over-year revenue decline of 4.8% to $1.06 billion.
• Research analysts have raised their price targets for Illumina, with estimates ranging from $90 to $128, and the stock currently holds an average rating of "Hold" with a price target of $124.58.

Vestmark Advisory Solutions Inc. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 38.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,830 shares of the life sciences company's stock after purchasing an additional 6,613 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Illumina were worth $1,891,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital World Investors boosted its stake in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after buying an additional 14,481,232 shares during the period. Brown Advisory Inc. grew its stake in shares of Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after purchasing an additional 1,909,118 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Illumina by 2,057.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after purchasing an additional 879,533 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after purchasing an additional 558,243 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Illumina by 2,292.9% in the 1st quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock valued at $44,881,000 after purchasing an additional 542,040 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 0.2%

Shares of ILMN traded up $0.2250 during trading hours on Thursday, hitting $101.0250. 263,463 shares of the stock traded hands, compared to its average volume of 2,333,473. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The firm has a market capitalization of $15.53 billion, a PE ratio of 12.81, a price-to-earnings-growth ratio of 2.28 and a beta of 1.37. The business has a fifty day moving average of $97.66 and a 200-day moving average of $89.50.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Barclays upped their price objective on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Robert W. Baird raised their price target on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday, July 28th. JPMorgan Chase & Co. lowered their price target on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, Daiwa America lowered Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Seven research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.